• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Nutriband CEO Publishes Letter to Shareholders

    4/30/25 7:30:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care
    Get the next $NTRB alert in real time by email

    ORLANDO, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2024 and the potential outlook for 2025. The full text of the letter is below.

    GS Headshot 1

    Dear Shareholders,

    Following the filing of our annual report as we wrap up a successful year packed with milestones and advances towards the commercialization of our AVERSA technology, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2024 and into 2025.

    Many of you have been with us from the beginning and many more joined our mission to change the pharmaceutical industry for the better by developing our Aversa technology designed to improve the safety of easily abused transdermal drugs, such as pain medications, while making them available to patients who need them.   Pain patients have been struggling with inadequate care for too long, and they deserve to be able to access the medication they need. Aversa gives them this access. Today we are on track to be the world's first and only abuse deterrent technology in the transdermal space targeting abusable medications such as fentanyl and buprenorphine.

    Nutriband is primarily focused on working with our partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop our lead product, AVERSA™ Fentanyl, which incorporates Nutriband's AVERSA™ abuse-deterrent transdermal technology into Kindeva's FDA-approved transdermal fentanyl patch.

    AVERSA Fentanyl has the potential to become the world's first opioid pain patch with abuse deterrent properties and is estimated to potentially reach peak annual sales of $80M - $200M. In addition, AVERSA Buprenorphine, our next candidate for AVERSA is projected to reach peak annual sales of $70M - $130M. Nutriband recently performed an extensive evaluation of the commercial cost of goods of incorporating the Aversa technology into existing FDA-approved transdermal patches and have confirmed the viability of achieving high margins that are typically found in NDA pharmaceutical products.

    This past year we have made significant strides in the development and scale-up of the manufacturing process to bring the AVERSA technology closer towards commercialization. This has involved the development and refinement of our proprietary technology for commercial scale manufacturability as well as the establishment of the commercial supply chain and validation of the analytical methods required to meet FDA regulatory standards for a pharmaceutical product.

    The new year has already been highlighted by a significant milestone with our partner Kindeva Drug Delivery to formalize our exclusive product development partnership and long-term commitment based on shared development costs in exchange for milestone payments. It solidifies a transition to commercial scale development for AVERSA Fentanyl. We have confidently shifted our focus from feasibility towards commercial development in support of an NDA filing and commercialization.   This was a very strong show of support from our partner Kindeva which also allowed us to reduce the impact of dilution to our existing shareholders which I stress has been and will remain a core focus of the company. This was evident through our raise of $8.4M USD in April 2024 in a non-brokered private placement primarily through existing shareholders.

    In addition, we continued to further expand the worldwide intellectual property portfolio for our Aversa™ abuse deterrent technology, with approvals in China and its territories, Hong Kong and Macao, and a new patent recently allowed in the United States. This improves our position to bring our leading abuse deterrent platform to market and we are now patented in 46 countries around the world. While initially concentrating on the US market, the unmet medical need for adequate pain management is a global problem, and our goal is to make AVERSA a global solution strategically targeting all major medical markets in the world.

    Our 2025 goals are ambitious yet achievable, focused on getting into the clinic to evaluate our lead product, Aversa Fentanyl, in a pivotal Human Abuse Liability (HAL) clinical trial to support an NDA filing. This involves manufacturing clinical supplies using a commercial scale process and filing an Investigational New Drug application with the FDA. We are also excited to explore new potential partnerships, internationally for our AVERSA intellectual property and will be turning our focus to potential licensing and partnership opportunities as we near closer to filing our NDA with the FDA.

    Financially, the team is excited by strong revenue in our Pocono Pharma subsidiary for our kinesiology tape contract manufacturing services. We strongly believe that 2025 is shaping up to be our best year on record at Pocono Pharma due to our expanding manufacturing collaboration with KT Tape, the world leader in kinesiology tape.

    If you haven't already taken a moment to sign up for our email alerts, be sure to do so by visiting our website: www.Nutriband.com. Signing up will ensure that you receive the latest news and announcements as they become available.

    Your continued support and belief in our vision have been pivotal to our reaching these milestones and others as we forge ahead. We remain committed to delivering innovative solutions and generating value for our shareholders. Thank you for your trust, confidence and investment in Nutriband Inc.



    Sincerely,

    GS signature

    Gareth Sheridan

    CEO, Nutriband Inc.

    About AVERSA™ Abuse-Deterrent Transdermal Technology

    Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

    About Nutriband Inc.

    We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

    The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

    Forward-Looking Statements

    Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Form 10-K for the year ended January 31, 2025, filed April 28, 2025, the Forms 10-Q's filed subsequent to the Form 10-K in 2025, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

    Contact Information:

    Nutriband Inc.

    Phone: 407-377-6695

    Email: [email protected]

    SOURCE: Nutriband Inc.

    Photos accompanying this announcement are available at: 

    https://www.globenewswire.com/NewsRoom/AttachmentNg/f4035a0b-b5f1-4167-91c8-f4f146dbeb5f

    https://www.globenewswire.com/NewsRoom/AttachmentNg/e3da803b-9190-4c1e-8907-1d43a54d110a



    Primary Logo

    Get the next $NTRB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NTRB

    DatePrice TargetRatingAnalyst
    1/22/2025$13.00Outperform
    Noble Capital Markets
    More analyst ratings

    $NTRB
    Leadership Updates

    Live Leadership Updates

    See more
    • Nutriband Appoints Accomplished Business Leader Sergei Glinka to its Board of Directors

      The Glinka family invested $4.5 million into Nutriband through the Company's April 2024 private placementORLANDO, FL / ACCESSWIRE / May 16, 2024 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a developer of transdermal pharmaceutical solutions, today announced the appointment of Sergei Glinka to its board of directors. Glinka is a seasoned and highly respected business executive with an impressive track record in leadership roles across major European companies.Mr. Glinka, an Estonian citizen, is an experienced and highly regarded businessman who has held numerous Executive and Board positions in large European Companies providing Glinka with deep insights and networks across various industri

      5/16/24 7:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nutriband Inc. to present at the 2025 Noble Capital Markets Virtual Equity Conference

      ORLANDO, Fla., June 03, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO, Gareth Sheridan will present at Noble Capital Markets' Emerging Growth Virtual Equity Conference on Thursday, June 5th at 4PM Eastern Standard Time. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.  Scheduled 1x1 meetings with the Company are also available for registered, qualified investor attendees. Attendees interested in viewing the live presentation can register for this event, at no cost, here: Virtual Equity Conference Registration A video webcast of the presentation will be available fol

      6/3/25 8:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Inc. Quarterly Report Highlights Record Revenue for Q1, 2025 up 63% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl

      ORLANDO, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the first quarter ended April 30, 2025. Nutriband is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry's largest brands. The Company produced a record first quarter reporting revenue of $667,000USD, up 63% % YOY. Pocono manufactured products continue to roll out into prominent retail locations nationwide, including Target, Walmart, Walgreens and CVS and the increasing Pocono revenue stream is key to the company's focus on shareholder v

      6/2/25 8:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • IBN Announces Latest Episode of The BioMedWire Podcast Featuring Gareth Sheridan, CEO of Nutriband Inc.

      AUSTIN, Texas, May 27, 2025 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews with industry experts at the forefront of pharmaceutical and biotech advancement. The latest episode features Gareth Sheridan, Co-Founder and CEO of Nutriband Inc. (NASDAQ:NTRB), a company engaged in the development of a portfolio of transdermal pharmaceutical products. Duri

      5/27/25 8:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    SEC Filings

    See more
    • SEC Form 10-Q filed by Nutriband Inc.

      10-Q - NutriBand Inc. (0001676047) (Filer)

      5/30/25 4:02:06 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Amendment: SEC Form 10-K/A filed by Nutriband Inc.

      10-K/A - NutriBand Inc. (0001676047) (Filer)

      5/13/25 5:29:18 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 10-K filed by Nutriband Inc.

      10-K - NutriBand Inc. (0001676047) (Filer)

      4/28/25 5:21:20 PM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Goodman Gerald

      4 - NutriBand Inc. (0001676047) (Issuer)

      12/2/24 3:49:25 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by President and Secretary Melnik Serguei

      4 - NutriBand Inc. (0001676047) (Issuer)

      11/29/24 1:58:08 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by CEO Sheridan Gareth

      4 - NutriBand Inc. (0001676047) (Issuer)

      11/29/24 1:11:33 PM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Financials

    Live finance-specific insights

    See more
    • Can-Fite BioPharma and Nutriband Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

      ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo

      5/10/24 9:00:00 AM ET
      $CANF
      $NTRB
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
    • Nutriband Inc. Commences Trading on Upstream Under NTRB

      Nutriband among the first issuers to dual list on UpstreamORLANDO, FL / ACCESSWIRE / January 5, 2023 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a pioneer in the science of using novel transdermal solutions and other innovative technologies, will become available today at 10:00am EST under the ticker symbol NTRB on Upstream, the revolutionary trading app for digital securities and NFTs powered by Horizon Fintex ("Horizon") and MERJ Exchange Limited ("MERJ"). Nutriband's digital collectible NFT commemorating the dual listing is also available for all Upstream participants to claim with the claim code "NTRB!".Global investors can now trade by downloading Upstream from their preferred app sto

      1/5/23 6:00:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • Nutriband Inc. Will Be the First Company to Dual List on Upstream

      Trading scheduled to Commence on Upstream January 5, 2023ORLANDO, FL / ACCESSWIRE / December 30, 2022 / Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW) announced today that it will be the first company to dual list on Upstream following recent approval."We are proud to have a trailblazer like Nutriband as the first company to dual list on Upstream and offer its shares to an international investor-base seeking streamlined access to U.S. companies," says Upstream Co-Founder Mark Elenowitz.The dual listing on Upstream is designed to provide Nutriband the opportunity to access a global, digital-first investor base that can trade using USDC digital currency along with credit, debit, PayPal, and USD, u

      12/30/22 6:30:00 AM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Nutriband Inc.

      SC 13D/A - NutriBand Inc. (0001676047) (Subject)

      9/19/24 11:38:15 AM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Nutriband Inc.

      SC 13G - NutriBand Inc. (0001676047) (Subject)

      2/13/24 8:33:52 PM ET
      $NTRB
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by Nutriband Inc.

      SC 13G - NutriBand Inc. (0001676047) (Subject)

      2/12/24 3:57:44 PM ET
      $NTRB
      Industrial Specialties
      Health Care

    $NTRB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Noble Capital Markets initiated coverage on Nutriband with a new price target

      Noble Capital Markets initiated coverage of Nutriband with a rating of Outperform and set a new price target of $13.00

      1/22/25 9:24:55 AM ET
      $NTRB
      Industrial Specialties
      Health Care